Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Aug 24, 2012

NEW YORK (GenomeWeb News) – The New York Genome Center has appointed Dirk Evers and Kevin Shianna to its leadership team.

Evers, who will serve as senior vice president of bioinformatics, joins NYGC from Illumina, where he led the company's computational biology efforts in the UK. Previously, he served as managing director of the International Graduate School in Bioinformatics and Genome Research at the Center for Biotechnology at Bielefeld University.

Shianna will serve as senior vice president of sequencing operations at the NYGC. He joins from Duke University, where he was an assistant professor in the School of Medicine, director of operations for the Center for Human Genome Variation, and founding director for the Genomic Analysis Facility.


Interleukin Genetics said this week that Lewis Bender has resigned from his positions as CEO and as a member of the board of directors. It has named current President and CSO Kenneth Kornman to fill the CEO and board posts.

Bender resigned to pursue other business opportunities, the company said, and he left the firm this week. Kornman will continue to perform his duties as president and CSO.


CombiMatrix has named Mark McDonough its new chief commercial officer, effective immediately. McDonough has 20 years of experience in diagnostics sales and business development. He most recently was VP of sales, customer service, and training at Pathwork Diagnostics, and he spent six years at USLabs/Dianon, where he eventually became VP of sales.


The French clinical data analysis company Ariana Pharma has tapped Mariana Kuras to serve as chief technology officer. Kuras previously was director of research at Biosystems International, where she developed biomarker technologies, and she was a genomics and bioinformatics scientist at Pfizer Global Research and Development. She also has been an independent scientific expert for the European Commission.


Rosetta Genomics said this week that Guy Malchi has joined the company as its EVP of corporate development. Malchi formerly was GM and head of pharma at Champions Oncology and CEO of Optimata, and he spent seven years at the management consulting firm TEFEN, where he was a founding partner and head of its European Life Science Practice.


Source BioScience has made some changes to its board of directors. Non-executive Director Robin Slinger, who has been a board member since 2004, has stepped down, and Robert Bakewell has been appointed as a member of the board. Bakewell joined Source Bioscience in 2005 and has served as finance director in a non-board capacity since 2011.


The University of Arkansas has selected Ravi Barabote, an assistant professor of biological sciences, to be the inaugural holder of its 21st Century Chair in Bioinformatics. Barabote's research combines microbial genomics, bioinformatics, and experimental molecular biology to understand various aspects of microbial physiology. He currently focuses on bioenergy and biofuel applications.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.